2022 Fiscal Year Final Research Report
Development of tailor-made iPS-DC cancer vaccine therapy targeting Neoantigen
| Project/Area Number |
20K09063
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山上 裕機 和歌山県立医科大学, 医学部, 学長特命教員(特別顧問) (20191190)
北谷 純也 和歌山県立医科大学, 医学部, 助教 (30596979)
中村 公紀 和歌山県立医科大学, 医学部, 非常勤講師 (80364090)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | がんワクチン / iPS細胞 / 樹状細胞 / ネオアンチゲン |
|---|
| Outline of Final Research Achievements |
In this study, we use amplified mRNA from human colorectal cancer cells, synthesized them by in vitro transcription, and transfected iPSDCs with in vitro transcriptional RNA (ivtRNA). We examine whether the ivtRNA-transfected iPSDCs induce tumor-specific cytotoxic T lymphocytes (CTLs) and whether these antitumor responses are directed against multiple TAAs.
Our studies clearly demonstrate that the high immunogenicity of iPSDCs-ivtRNA was generated by transfecting tumor RNA. By transfecting ivtRNA of CTOSs prepared from surgical specimens into iPSDCs generated from patients with colorectal cancer, we succeeded in inducing CTLs in vitro for the first time. In addition, these CTLs showed an immune response to a neoantigen. Ultimately, our findings revealed that iPSDCs-ivtRNA paves the way for a promising DC vaccine therapy.
|
| Free Research Field |
消化管外科
|
| Academic Significance and Societal Importance of the Research Achievements |
我々の研究の最終目標は各患者由来iPS細胞を駆使した個別のiPS-DCワクチン療法という究極のテーラーメイドがんワクチン療法の構築である．
今回の研究におけるiPS-DCワクチン療法の研究成果は前臨床試験として世界にインパクトを与えるとともに，多くの難治性消化器固形癌患者に大きな希望を与えると確信する．
|
